{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:05:03Z","timestamp":1790701503044,"version":"4.1.0"},"reference-count":40,"publisher":"IMR Press","issue":"9","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Department of Defense","award":["DoD CA-210339"],"award-info":[{"award-number":["DoD CA-210339"]}]},{"name":"National Institutes of Health","award":["NIH-P30GM154635"],"award-info":[{"award-number":["NIH-P30GM154635"]}]},{"name":"Oklahoma Center for the Advancement of Science and Technology","award":["OCAST-HR19-045"],"award-info":[{"award-number":["OCAST-HR19-045"]}],"id":[{"id":"https:\/\/ror.org\/02q578v20","id-type":"ROR","asserted-by":"crossref"}]},{"name":"NIH-NCI- Cancer Center Support Grant","award":["P30CA225520"],"award-info":[{"award-number":["P30CA225520"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>Background: Progressive disease (PD) remains the dominant barrier to cure in high-risk neuroblastoma (HR-NB), driven in part by profound post-transcriptional deregulation that fuels clonal evolution, stemness, immune evasion, and therapy resistance. In this study, we define the molecular architecture of PD-associated microRNA (miR) collapse and demonstrate that radiotherapy (RT) acts as a potent post-transcriptional reprogrammer capable of reversing this trajectory. Methods: miRNome profiling was performed in HR-NB tumors from patients during diagnosis (Dx), intensive multi-modal clinical therapy (IMCT) defiant PD, or residual disease after incorporating RT with IMCT (RD-RT). miRs\u2019 expression profiles were validated with selective miR-320a, miR-423, miR-483-3p, miR-122-5p, miR-3184-5p, miR-21-5p qPCR. RT-influenced changes in cell-identity were investigated by assessing histomorphological alterations (H&amp;E) and multiplex immunofluorescence (mIF) for Ki-67, PD-L1, SOX2, CD44 or p53. Results: IMCT-defying PD displayed a loss of 167 miRs, and none upregulated, corresponding an evolutionary fingerprint for pathways governing cancer stem cell (CSC) maintenance, epithelial to mesenchymal transition (EMT), metabolic rewiring, proliferative fitness, and immune suppression. Strikingly, adding RT reversed 146 of these miRs and induced additional 179 RT-specific miRs, restoring regulatory networks governing apoptosis, p53-mediated DNA-damage response, differentiation\/mesenchymal to epithelial transition (MET), and immune visibility. Individual miR-qPCR analysis of miR-320a, miR-483-3p, miR-3184-5p miR-21-5p, and miR-122-5p validated and corroborated the array expression outcomes. Histologic and mIF remarkably substantiated these miR signatures, showing that RT transforms poorly differentiated, plastic, PD-L1+\/SOX2+\/CD44+ CSC-like PD tumors into differentiated, lineage-stabilized, immune-permissive states characterized by neuropil restoration, ganglioneuroma-like maturation, marginal yet measurable loss of SOX2\/CD44, suppression of PD-L1, complete collapse of Ki-67+ proliferative compartments, and significant induction of p53. Conclusion: Collectively, our findings indicated that RT could be a global regulator of tumor state transitions, reinstating miR-mediated governance lost during PD evolution and redirecting tumor fate toward regression. Our results provide proof-of-concept evidence that RT delivers powerful molecular benefits beyond local control, introducing a conceptual framework for miR-guided RT personalization, biomarker development, and rational combination strategies to improve outcomes in HR-NB.<\/jats:p>","DOI":"10.31083\/fbl52737","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:21:51Z","timestamp":1790698911000},"source":"Crossref","is-referenced-by-count":0,"title":["Radiotherapy Reconstitutes the Collapsed miRNome of Progressive Neuroblastoma and Promotes a Favorable Tumor Evolutionary Shift"],"prefix":"10.31083","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2378-3961","authenticated-orcid":true,"given":"Sivasubramani","family":"Narayanan","sequence":"first","affiliation":[{"name":"Department of Physiological Sciences, College of Veterinary Medicine, Oklahoma State University, Stillwater, OK 74078, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9604-0397","authenticated-orcid":true,"given":"Poorvi","family":"Subramanian","sequence":"additional","affiliation":[{"name":"Department of Physiological Sciences, College of Veterinary Medicine, Oklahoma State University, Stillwater, OK 74078, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1694-2882","authenticated-orcid":true,"given":"Sreenidhi","family":"Mohanvelu","sequence":"additional","affiliation":[{"name":"Department of Physiological Sciences, College of Veterinary Medicine, Oklahoma State University, Stillwater, OK 74078, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4810-789X","authenticated-orcid":true,"given":"Sheeja","family":"Aravindan","sequence":"additional","affiliation":[{"name":"OU Health Stephenson Cancer Center, Oklahoma City, OK 73104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7333-4120","authenticated-orcid":true,"given":"Loganayaki","family":"Periyasamy","sequence":"additional","affiliation":[{"name":"Department of Physiological Sciences, College of Veterinary Medicine, Oklahoma State University, Stillwater, OK 74078, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9150-3911","authenticated-orcid":true,"given":"Natarajan","family":"Aravindan","sequence":"additional","affiliation":[{"name":"Department of Physiological Sciences, College of Veterinary Medicine, Oklahoma State University, Stillwater, OK 74078, USA"},{"name":"OU Health Stephenson Cancer Center, Oklahoma City, OK 73104, USA"},{"name":"Departments of Radiation Oncology and Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Crane JN, Dagalakis U, Gartrell RD, Schultz KAP, Laetsch TW. Rare but not forgotten: Therapeutic advancements for rare childhood cancers. Molecular Therapy. Oncology. 2025; 33: 201084.","DOI":"10.1016\/j.omton.2025.201084"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"George NG, Rishi B, Dhanda H, Joseph GT, Swain SK, Kaur M, et al. Pediatric tumor microenvironment: developmental dynamics and therapy resistance. Frontiers in Oncology. 2025; 15: 1663975.","DOI":"10.3389\/fonc.2025.1663975"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"DuBois SG, Macy ME, Henderson TO. High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2022; 42: 768\u2013780.","DOI":"10.1200\/EDBK_349783"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Chan GC, Hindsberger C, Morsing A, Lisby S. Naxitamab and granulocyte macrophage colony stimulating factor (GM-CSF) in combination with irinotecan and temozolomide in patients with high-risk neuroblastoma with primary refractory disease or in first relapse: An international, single-arm, multicenter phase 2 trial. Journal of Clinical Oncology. 2022; 40: TPS10061.","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS10061"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Richards RM, Sotillo E, Majzner RG. CAR T Cell Therapy for Neuroblastoma. Frontiers in Immunology. 2018; 9: 2380.","DOI":"10.3389\/fimmu.2018.02380"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Zhou X, Wang X, Li N, Guo Y, Yang X, Lei Y. Therapy resistance in neuroblastoma: Mechanisms and reversal strategies. Frontiers in Pharmacology. 2023; 14: 1114295.","DOI":"10.3389\/fphar.2023.1114295"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Li F, Zhang W, Hu H, Zhang Y, Li J, Huang D. Factors of Recurrence After Complete Response in Children with Neuroblastoma: A 16-Year Retrospective Study of 179 Cases. Cancer Management and Research. 2022; 14: 107\u2013122.","DOI":"10.2147\/CMAR.S343648"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Romero LE, Neto IQ, Antunes VL, Rodrigues MM, Mercado JP, Caran EM. 1030P Survival rates in high-risk neuroblastoma patients undergoing anti-GD2 immunotherapy: A single arm meta-analysis and systemic review. Annals of Oncology. 2024; 35: S694\u2013S695.","DOI":"10.1016\/j.annonc.2024.08.1089"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Bahmad HF, Chamaa F, Assi S, Chalhoub RM, Abou-Antoun T, Abou-Kheir W. Cancer Stem Cells in Neuroblastoma: Expanding the Therapeutic Frontier. Frontiers in Molecular Neuroscience. 2019; 12: 131.","DOI":"10.3389\/fnmol.2019.00131"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Zhao Q, Liu Y, Zhang Y, Meng L, Wei J, Wang B, et al. Role and toxicity of radiation therapy in neuroblastoma patients: A literature review. Critical Reviews in Oncology\/hematology. 2020; 149: 102924.","DOI":"10.1016\/j.critrevonc.2020.102924"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Jazmati D, Hero B, Thole-Kliesch TM, Merta J, Deubzer HE, B\u00e4umer C, et al. Efficacy and Feasibility of Proton Beam Therapy in Relapsed High-Risk Neuroblastoma-Experiences from the Prospective KiProReg Registry. Current Oncology (Toronto, Ont.). 2022; 29: 8222\u20138234.","DOI":"10.3390\/curroncol29110649"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Gatcombe HG, Marcus RB Jr, Katzenstein HM, Tighiouart M, Esiashvili N. Excellent local control from radiation therapy for high-risk neuroblastoma. International Journal of Radiation Oncology, Biology, Physics. 2009; 74: 1549\u20131554.","DOI":"10.1016\/j.ijrobp.2008.10.069"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Mestdagh P, Bostr\u00f6m AK, Impens F, Fredlund E, Van Peer G, De Antonellis P, et al. The miR-17-92 microRNA cluster regulates multiple components of the TGF-\u03b2 pathway in neuroblastoma. Molecular Cell. 2010; 40: 762\u2013773.","DOI":"10.1016\/j.molcel.2010.11.038"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Aravindan N, Subramanian K, Somasundaram DB, Herman TS, Aravindan S. MicroRNAs in neuroblastoma tumorigenesis, therapy resistance, and disease evolution. Cancer Drug Resistance (Alhambra, Calif.). 2019; 2: 1086\u20131105.","DOI":"10.20517\/cdr.2019.68"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Khan FH, Pandian V, Ramraj S, Aravindan S, Herman TS, Aravindan N. Reorganization of metastamiRs in the evolution of metastatic aggressive neuroblastoma cells. BMC Genomics. 2015; 16: 501.","DOI":"10.1186\/s12864-015-1642-x"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Southgate HED, Chen L, Curtin NJ, Tweddle DA. Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma. Frontiers in Oncology. 2020; 10: 371.","DOI":"10.3389\/fonc.2020.00371"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Berglund H, Salomonsson SL, Mohajershojai T, Gago FJ, Lane DP, Nestor M. p53 stabilisation potentiates [(177)Lu]Lu-DOTATATE treatment in neuroblastoma xenografts. European Journal of Nuclear Medicine and Molecular Imaging. 2024; 51: 768\u2013778.","DOI":"10.1007\/s00259-023-06462-3"},{"key":"ref18","unstructured":"Xu Y, Chen K, Cai Y, Cheng C, Zhang Z, Xu G. Overexpression of Rad51 predicts poor prognosis and silencing of Rad51 increases chemo-sensitivity to doxorubicin in neuroblastoma. American Journal of Translational Research. 2019; 11: 5788\u20135799."},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Le Grand M, Mukha A, P\u00fcschel J, Valli E, Kamili A, Vittorio O, et al. Interplay between MycN and c-Myc regulates radioresistance and cancer stem cell phenotype in neuroblastoma upon glutamine deprivation. Theranostics. 2020; 10: 6411\u20136429.","DOI":"10.7150\/thno.42602"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Jadhav U, Mohanam S. Response of neuroblastoma cells to ionizing radiation: modulation of in vitro invasiveness and angiogenesis of human microvascular endothelial cells. International Journal of Oncology. 2006; 29: 1525\u20131531.","DOI":"10.3892\/ijo.29.6.1525"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Hein AL, Ouellette MM, Yan Y. Radiation-induced signaling pathways that promote cancer cell survival (review). International Journal of Oncology. 2014; 45: 1813\u20131819.","DOI":"10.3892\/ijo.2014.2614"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Ahmed KM, Li JJ. NF-kappa B-mediated adaptive resistance to ionizing radiation. Free Radical Biology & Medicine. 2008; 44: 1\u201313.","DOI":"10.1016\/j.freeradbiomed.2007.09.022"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Ramraj SK, Aravindan S, Somasundaram DB, Herman TS, Natarajan M, Aravindan N. Serum-circulating miRNAs predict neuroblastoma progression in mouse model of high-risk metastatic disease. Oncotarget. 2016; 7: 18605\u201318619.","DOI":"10.18632\/oncotarget.7615"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Subramanian P, Mohanvelu S, Aravindan S, Jahir Hussain AP, Narayanan S, Salim S, et al. Cellular Identity Crisis: RD3 Loss Fuels Plasticity and Immune Silence in Progressive Neuroblastoma. Advanced Science (Weinheim, Baden-Wurttemberg, Germany). 2026; 13: e19586.","DOI":"10.1002\/advs.202519586"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Singh J, Thachil T, Misir S, Altay DU, Yaman SO, Singh G, et al. Expression of microRNAs following radiation therapy and association with severity of radiotherapy-induced toxicity among patients with prostate adenocarcinoma: A systematic review and meta-analysis. World Academy of Sciences Journal. 2024; 6: 27.","DOI":"10.3892\/wasj.2024.242"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Chen H, Han Z, Luo Q, Wang Y, Li Q, Zhou L, et al. Radiotherapy modulates tumor cell fate decisions: a review. Radiation Oncology (London, England). 2022; 17: 196.","DOI":"10.1186\/s13014-022-02171-7"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Qiu B, Matthay KK. Advancing therapy for neuroblastoma. Nature Reviews. Clinical Oncology. 2022; 19: 515\u2013533.","DOI":"10.1038\/s41571-022-00643-z"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Guo Q, Yang W, Robinson G, Chaludiya K, Abdulkadir AN, Roy FG, et al. Unlocking the Radiosensitizing Potential of MYC Inhibition in Neuroendocrine Malignancies. International Journal of Radiation Oncology, Biology, Physics. 2025; 122: 1310\u20131326.","DOI":"10.1016\/j.ijrobp.2025.04.034"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Huang RX, Zhou PK. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduction and Targeted Therapy. 2020; 5: 60.","DOI":"10.1038\/s41392-020-0150-x"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Nickoloff JA, Taylor L, Sharma N, Kato TA. Exploiting DNA repair pathways for tumor sensitization, mitigation of resistance, and normal tissue protection in radiotherapy. Cancer Drug Resistance (Alhambra, Calif.). 2021; 4: 244\u2013263.","DOI":"10.20517\/cdr.2020.89"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Chen X, Zhao G, Wang F, Gao F, Luo H, Wang Y, et al. Upregulation of miR-513b inhibits cell proliferation, migration, and promotes apoptosis by targeting high mobility group-box 3 protein in gastric cancer. Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine. 2014; 35: 11081\u201311089.","DOI":"10.1007\/s13277-014-2405-z"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Moloudi K, Haghdoost S. An Update on Role of Ionizing Radiation to Enhance Proliferation and Differentiation of Normal Stem Cells via Activation of NRF2 Pathway: Review. Antioxidants (Basel, Switzerland). 2025; 14: 986.","DOI":"10.3390\/antiox14080986"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Marinova L, Vassileva V, Petrov V. Palliative 3D conformal radiotherapy of children's neuroblastoma non-resectable liver metastasis: clinical case with literature overview. Journal of Gastroenterology Pancreatology and Hepatobilary Disorders. 2022; 6: 054.","DOI":"10.31579\/2641-5194\/054"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Ritner C, Popovi\u0107 J, Abouzeid A, Li Y, Paunesku T, Papineni R, et al. Gene Expression and Early Radiation Response of Two Distinct Neuroblastoma Cell Lines. Oncology. 2023; 101: 446\u2013456.","DOI":"10.1159\/000530902"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Jonas S, Izaurralde E. Towards a molecular understanding of microRNA-mediated gene silencing. Nature Reviews. Genetics. 2015; 16: 421\u2013433.","DOI":"10.1038\/nrg3965"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Smith V, Foster J. High-Risk Neuroblastoma Treatment Review. Children (Basel, Switzerland). 2018; 5: 114.","DOI":"10.3390\/children5090114"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Wu L, Chen Z, Zhang J, Xing Y. Effect of miR-513a-5p on etoposide-stimulating B7-H1 expression in retinoblastoma cells. Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban. 2012; 32: 601\u2013606.","DOI":"10.1007\/s11596-012-1004-8"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Cellini F, Morganti AG, Genovesi D, Silvestris N, Valentini V. Role of microRNA in response to ionizing radiations: evidences and potential impact on clinical practice for radiotherapy. Molecules (Basel, Switzerland). 2014; 19: 5379\u20135401.","DOI":"10.3390\/molecules19045379"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Roth SA, Knutsen E, Fiskaa T, Utnes P, Bhavsar S, Hald \u00d8H, et al. Next generation sequencing of microRNAs from isogenic neuroblastoma cell lines isolated before and after treatment. Cancer Letters. 2016; 372: 128\u2013136.","DOI":"10.1016\/j.canlet.2015.11.026"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Hill-Kayser CE, Tochner Z, Li Y, Kurtz G, Lustig RA, James P, et al. Outcomes After Proton Therapy for Treatment of Pediatric High-Risk Neuroblastoma. International Journal of Radiation Oncology, Biology, Physics. 2019; 104: 401\u2013408.","DOI":"10.1016\/j.ijrobp.2019.01.095"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/9\/10.31083\/FBL52737","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:23:00Z","timestamp":1790698980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/9\/10.31083\/FBL52737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2768-6701(26)02241-0"],"URL":"https:\/\/doi.org\/10.31083\/fbl52737","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"value":"2768-6701","type":"print"},{"value":"2768-6698","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"52737"}}